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ABSTRACT: This review focuses on vascularization and strategies involved in its evaluation
and modulation. Clinical issues associated with engineered tissues of an atomically relevant size
that require a vascular network to supply their cells with nutrients and oxygen are analyzed in
terms of vascular network formation within scaffolds, which can be produced from varying
biomaterials, with the capability of connecting to the vasculature of the patient. Developing
angiogenesis techniques and monitoring of angiogenesis development as well as how these
methods can be further utilized to tailor vascularization within large tissue engineered
constructs are also discussed. Finally, we offer a glimpse toward the future by providing an
outlook for vascularization and associated emerging bioprinting concepts in tissue engineering
applications.
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1. INTRODUCTION
In healthy biological systems, a constant supply of nutrients
and oxygen is essential. This is achieved by the vascular system,
which is formed during embryonic development and continues
to develop throughout adulthood (Figure 1).1 During the
natural development of the aforementioned system, there can
be two defined processes: (i) vasculogenesis, regarding the
formation of new blood vessels, and (ii) angiogenesis,
corresponding to the development of blood vesssels from a
pre-existing vascular network.2 Angiogenesis occurs in
response to various distinct pro-angiogenic signals released
by a tissue in need of oxygen and nutrients. Additionally, blood
vessels can also naturally regress in response to a functional
demand. For example, angiogenesis in the muscles is
stimulated by exercise, whereas weight loss leads to capillary
regression in adipose tissue.3
Abnormal angiogenesis can lead to several illnesses such as
stroke, myocardial infarction, cancer, among others. Thus,
understanding and controlling the angiogenic process can
allow us to envision the development of novel and powerful
therapeutic approaches.4 The angiogenic response can depend
on the functional demand of a tissue or cell, meaning that it
displays different characteristics when considering the type of
tissue, individual age, and physiological/pathological states.
However, the process itself is composed of four main steps
(Figure 2) and it can involve several cell types, extracellular
matrix (ECM) components, growth factors, and cytokines.4
First, there is vascular sprouting (Figure 2b,c), where the
endothelial cells leave their quiescent behavior in response to
pro-angiogenic signals and start to proliferate. These signals
include vascular endothelial growth factor (VEGF), fibroblast
growth factors (FGF), angiopoietins, and hypoxia inducible
factors, and they can either be released by a tissue in demand
of oxygen and nutrients or by injured cells. Second, there is
tubule morphogenesis (Figure 2d), where a lumen is
developed with the help of fibroblasts secreting tubulo-
genesis-stimulating molecules and ECM molecules. The third
step corresponds to the adaptation to tissue needs (Figure 2e)
where the newly formed vessel sprouts either regress or
stabilize. This is defined once more by the tissue or cell that
initiated the angiogenic process. If there is a sudden loss of the
pro-angiogenic factors and there is no blood flowing through
the new vessels, the tubes regress and undergo apoptosis.
Conversely, a mixture of a specific cocktail of angiogenic
factors such as VEGF, platelet-derived growth factor (PDGF),
Ang-1, Ang-2, and blood flow stabilizes the new endothelial
tubes. The last step corresponds to vessel stabilization (Figure
2a−e) where the proliferative state of the endothelial cells is
replaced by a quiescent one; blood flow is adjusted in the new
sprouts with adhesion between adjacent cells and to the ECM
Received: January 15, 2021
Accepted: March 18, 2021
Reviewwww.acsabm.org
© XXXX American Chemical Society
A
https://doi.org/10.1021/acsabm.1c00051
































































































re-established. PDGF, shingosine 1, Ang-1, and transforming
growth factor β (TGF-β), along with the ECM and the blood
flow, have been acknowledged as important contributors to
this stabilization step.4,5
In tissue engineering (TE), the goal is to replace damaged
biological tissues with substitutes that mimic their morphology
and function. Thus, proper vascularization of those substitutes
is essential upon implantation into the patient, especially in
large-size grafts. In small implants, the diffusion of nutrients
and oxygen from the pre-existing vasculature is enough to
maintain cell viability. However, in larger implants, this
diffusion only reaches the outer cell layers leading to the cell
death in the core. In fact, a healthy distance between a blood
supply and living cells should be around 200 μm.2
Vascularization of implanted tissues not only allows the supply
of nutrients and oxygen, and the exchange of metabolites, but
also enables the presence of highly specialized cells within the
graft, which contributes to tissue regeneration and remodel-
ing.6 There are several approaches that can be used to
understand and monitor the angiogenic process and to better
foster the integration of blood supply in larger constructs. Such
advanced approaches will be further discussed throughout this
review.
Angiogenesis has been the subject of previous reviews
focusing on wound models,7 functionalized biomaterials,8
tumors,9 mitochondria10 and growth factors,11 ECM influences
on blood vessel formation,12 and its role in TE strategies.13
However, this review provides an in-depth discussion on the
biomaterials engineering aspects of angiogenesis. In addition,
the recent biomaterial developments that are leading to new
strategies for vasculature creation within tissue scaffolds are
also overviewed. The role of angiogenesis in vascularization of
varying tissue constructs (e.g., scaffolds, cell sheets, 2D
patterning) as well as biomaterial, growth factor influences,
and in situ strategies are also discussed herein. This review also
covers the latest advancements in angiogenesis assessment
techniques both in vitro and in vivo, enabling an evaluation of
the behavior of scaffolds before implantation in its final target
tissue. Preclinical and post clinical (where available) data are
discussed. These reveal the importance of developing novel
approaches by addressing the angiogenic potential. From using
sequential delivery of growth factors as a potential treatment
for ischemia,14 to the development of biomimetic induced
membranes for bone defect repair,15 these strategies show how
relevant it is to understand this concept and how it can be used
for regeneration and tissue engineering purposes. Finally, the
details on how growth factors, scaffold design, cell-based
Figure 1. Simplified version of the cardiovascular system (not to
scale). (a) Cardiovascular system, which includes the heart and blood
vessels, is responsible for not only carrying hormones, which are
elements of the immune system but also enabling cells to exchange
nutrients, waste and gases, and other molecules all through the body.
(b) Arterioles are connected to the venules by capillaries. (c) Blood
flowing from oxygenated arterioles into capillaries enables solute
exchange at tissue interface: nutrients and oxygen are delivered to the
tissue, and CO2 and other metabolic byproducts are taken up by
blood. Thus, a strong and functional capillary network linked to the
circulatory system is essential for regenerative purposes. Reproduced
with permission from ref 1. Copyright 2019, Elsevier.
Figure 2. Schematic representation of the angiogenic process. (A)
Stable blood vessel. (B, C) Vascular sprouting. The release of pro-
angiogenic signals from a tissue in need of oxygen and nutrients is
recognized by the receptors present in the vessel. Pericytes
surrounding the endothelial cells detach and degrade the basement
membranes by expressing matrix metalloproteases. Fibroblasts
produce a provisional extracellular matrix for the new vessel sprout.
The bud of the sprout includes the tip cells, with ability to migrate,
and stalk cells, which proliferate and contribute to the elongation of
the vessel sprout. (D) Tubule morphogenesis. The endothelial cells
proliferate out of the parent vessels and acquire a lumen via
pinocytosis of vacuoles formed by the endothelial and stalk cells.
These vacuoles merge and span the multiple endothelial cells.
Fibroblast produces tubulogenesis-stimulating molecules inducing
tube formation. (E) Adaptation to tissue needs and stabilization/
maturation. Once the new vessel reaches the tissue in need, there is
vascular regression, and the new vessel stabilizes and matures. The
release of stabilizing signals along with the presence of blood flow
within the new vessel triggers the stabilization and maturation of the
sprout. The endothelium returns to its quiescent behavior, blood flow
is directed to the new vessel and adhesion between adjacent cells and
also between the cells and the extracellular matrix is re-established.
Pericytes are recruited to the vessel, matrix degradation is inhibited,
and a new basement membrane is produced for the new vessel.
Pericytes and extracellular matrix are also responsible for inhibiting
endothelial migration and proliferation and provide pro-survival
signals to the endothelial cells. 1, pericyte; 2, endothelial cell (EC); 3,
leukocyte; 4, erythrocyte; 5, EC receptor; 6, pro-angiogenic paracrine
signals; 7, tissue in need of oxygen and nutrients; 8, stalk cell; 9, tip
cell; 10, lumen formation; 11, stabilizing signals; 12, new mature
vessel.
ACS Applied Bio Materials www.acsabm.org Review
https://doi.org/10.1021/acsabm.1c00051
ACS Appl. Bio Mater. XXXX, XXX, XXX−XXX
B
strategies, and molecule immobilization techniques can infer
the benefits to angiogenesis and subsequent vascularization are
addressed. Vascularization in tissue engineering is still a
limitation due to nutrient and oxygen diffusion, which
subsequently impacts the ability to develop constructs with
clinically relevant dimensions and their integration in vivo.
Thus, understanding and developing ways to improve the
functionalization of the materials used is crucial.
2. VASCULARIZATION APPROACHES IN TISSUE
ENGINEERED CONSTRUCTS
The vascularization of tissue engineered constructs is essential
for their successful implantation and functionality in vivo.
Upon implantation of the construct, oxygen and nutrients
diffuse passively from surrounding blood vessels, providing a
rich environment to maintain viability of small grafts. However,
in bigger constructs, this passive diffusion of oxygen and
nutrients does not reach their core, and this can lead to a
hypoxic environment that eventually results in apoptosis.16
2.1. Classical Strategies. A classical strategy focuses on
the stimulation of vascularization within the tissue construct,
and this is achieved through optimization of scaffold materials
or by using growth factor delivery systems (Figure 3).16,17
Scaffolds can be combined with differing growth factors,
allowing cell attachment and the creation of a 3D environment
for cell-to-cell communication, thus enabling angiogenesis to
occur after implantation. Since the materials used for scaffold
production will interact with vascular cells, their selection is
crucial and largely dictated by implantation location. These
materials should be biocompatible, biodegradable, nontoxic,
and mimic the local ECM.18,19 Density, stiffness, viscoelas-
ticity, degradation, and the presence of integrin-binding motifs
are some of the ECM features that must be considered.19
2.1.1. Optimization of Scaffold Materials. Designing
angiogenic biomaterials that enable vascularization and cell
recruitment is especially important for the formation of
revascularized tissue into the implants. Strategies for the
development of such biomaterials include tailoring their
physicochemical properties and pore architecture.20 Surface
chemistry has been described to influence angiogenesis as it is
recognized by the surrounding cells. The addition of molecules
such as RGD and YIGSR peptides to metallic surfaces have
been explored to promote human umbilical vein endothelial
cells (HUVECs) adhesion in culture.21 Fibronectin is involved
in integrin signaling of endothelial cells and coating with this
material has been performed.22 Nanopatterning using
fibronectin was also explored23 revealing an influence on
proliferation of endothelial cells depending on its density,
adhesion size, and distance between fibronectin islands.
Surface topography, such as pillars, pits, grooves, tubes, fibers,
etc., can also be an important cue to promote angiogenesis.
Bettinger et al.24 used ridge-groove grating substrates that
resulted in enhanced tubular formation and organization of
endothelial progenitor cells. Kim et al.25 showed that different
surface patterns created using nanotopography can stimulate
the secretion of different angiogenic molecules. Stiffness is
another biomaterial property that can influence the formation
of vascular networks. For example, endothelial cells cultured on
stiff type-I collagen hydrogels produced more actin stress fibers
when compared to ones cultured on soft type-I collagen
hydrogels.26 Another example of how stiffness can be used to
modulate endothelial cells is the work developed by Santos et
al.,27 where HUVECs cultured on collagen-coated polyacryla-
mide (PAAm) hydrogels with different stiffness levels
influenced the expression of pro-angiogenic and osteogenic
factors. Degradation rate of the biomaterial used is also a
particularly important cue for cellular behavior. Fibrin gel
matrices, for example, have been developed with covalently
bonded VEGF variant. Ehrbar et al.28 showed a controlled
VEGF variant release upon cell matrix degradation, giving rise
Figure 3. Five different approaches to stimulate angiogenesis: (a, b) in vitro and in vivo prevascularization strategies; (c) by means of adding growth
factors; (d) by means of adding adhesion peptides; (e) co-culturing different cell types. Reproduced with permission from ref 13. Copyright 2010,
Elsevier.
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to a superior neovessel formation. Finally, the pore architecture
can also be tuned to maximize vascularization of constructs.
Calcium phosphate (CaP) was used to prepare particles with
several pore sizes, and their ability to induce angiogenesis was
assessed in a critical-sized cranial defect in mice. Bigger pore
sizes showed higher functional capillary density.29 Porous
hydrogels have also been studied to improve vessel formation.
PEG hydrogels with different pore sizes were developed and
tissue in growth was evaluated in 3D cell culture and rodent
models. Smaller pores lead to lower vessel invasion, whereas
bigger pores promoted a deeper vascular ingrowth.30 Besides
the size of the pore itself, the porosity in the scaffold is also
relevant for vessel formation. Walthers et al.31 developed
electrospun scaffolds with a range of porosity from 15−25%
and showed significantly higher blood vessel infiltration in
higher porosity range. Pore interconnection should also be
considered, as it determines the area and number of blood
vessels in the construct. CaP scaffolds with different
interconnection sizes and similar pore sizes were evaluated in
a rabbit femoral condyle, showing significantly improved
revascularization for higher interconnection size values.32
Somo et al.33 developed PEG hydrogels with controlled pore
interconnectivity by sacrificial poly(methyl methacrylate)
(PMMA) microspheres. Higher pore interconnectivity led to
complete vascularization within 3 weeks, whereas lower pore
interconnectivity showed limited vascularization. The bio-
material itself can also influence vascularization. Several
synthetic polymers have been developed for this purpose.
Polyglycolic acid (PGA), for example, is a biodegradable
polymer that promotes neovascularization. Li et al.34 have
shown that vascularization of an islet graft can be greatly
improved by culturing endothelial cells on a PGA scaffold. Poly
lactic acid (PLA)-derived materials are also frequently used.
For example, Caldara et al.35 demonstrated the angiogenic
potential of poly-L-lactid acid (PLLA) by implanting PLLA
disks into dorsal subcutis of mice. Some nondegradable
synthetic polymers have also been used for tissue vasculariza-
tion. For example, vascularization potential of different
polyurethane scaffolds was studied by Laschke et al.36
However, synthetic materials present some disadvantages,
namely the absence of bioactive molecules within their
molecular structure.18
Natural polymers have also been explored. Collagen, a main
component of the ECM, offers porosity, permeability,
biocompatibility, and biodegradability.37 Chen et al.14 studied
the performance of a three-dimensional (3D) collagen-based
scaffold by assessing its biological responses in vitro and in vivo.
Besides enabling cell adhesion, promoting cell growth and
osteogenic differentiation of rat mesenchymal stem cells
(MSCs) in vitro, this scaffold also demonstrated an ability to
recruit and differentiate MSCs from subcutaneous tissue, and it
enabled angiogenesis. Chan et al.38 demonstrated the
vascularization potential of a porous 3D collagen scaffold
implanted in vivo. Fibrin is formed during blood clotting and
provides a suitable environment for angiogenesis. However,
because of its poor mechanical properties and fast degrad-
ability, fibrin is mainly used as a composite.39,40 Urech et al.41
used a fibrin matrix to show that its features could be tailored
to become biologically stimulating and promote angiogenesis.
Jiang et al.42 used porous poly(ethylene glycol) (PEG)
hydrogels loaded with fibrin and demonstrated fibrin’s ability
to induce vascularization by using the PEG hydrogels alone as
a control. Elastin is a protein from the connective tissue and
has been greatly investigated for vessel formation. Schmidt et
al.43 used arteriovenous (AV) loops loaded with collagen-
elastin and collagen-glycosaminoglycan scaffolds and showed
homogeneous vessel formation. Silk fibroin has also been
described for tissue vascularization. Unger et al.44 developed
microcapillary-like structures formed by endothelial cells,
osteoblast cells, and silk fibroin scaffolds; they were implanted
in immune-deficient mice. The in vitro preformed micro-
capillaries were not only anastomosed to the host vasculature
but also stimulated the rapid growth of host capillaries into and
within the implanted material. Li et al.45 investigated the
neovascularization and biodegradation of silk fibroin scaffolds
in vivo. They observed an enhancement in vascularization after
20 days of implantation. Alginate is a polysaccharide from
brown seaweed and bacteria. Alginate hydrogels are highly
hydrated, and this promotes cell viability, but they lack
attachment sites for vascular cells.46 Therefore, the possibility
to cross-link peptides and incorporate angiogenic factors and
adsorbed proteins has been studied. Nemati et al.47
investigated how alginate-gelatin encapsulation affected the
angiogenic behavior of human endothelial cells. In vitro, the
authors studied the expression of specific genes that were
correlated with angiogenesis in endothelial cells and in vivo,
injection of the microcapsules into muscular tissue of mice was
performed to evaluate the angiogenic capacity. The results
obtained suggested that the alginate-gelatin capsules can
induce an angiogenic response in vivo and in vitro. Gerecht-
Nir et al.48 have shown that the pores present in alginate
scaffolds induce vasculogenesis in human embryoid bodies
(hEBs). Chitosan is a carbohydrate biopolymer used in TE due
to its biocompatibility, biodegradability, nontoxicity, and
nonimmunogenicity.49 Recently, Hsieh et al.50 developed a
chitosan-fibrin (CF)-based self-healing hydrogel that enables
the formation of capillary-like structures when vascular
endothelial cells were seeded, and promotes angiogenesis
when injected in the perivitelline space of zebrafish. Malafaya
et al.51 demonstrated that chitosan scaffolds produced by the
particle aggregation method promoted neovascularization,
even in early stages of implantation. Hyaluronic acid (HA) is
a nonsulfated glycosaminoglycan present in connective,
epithelial, and neural tissues.52 Silva et al.52 developed gellan-
gum (GG)-HA spongy-like hydrogels and implanted them in
mice, promoting neovascularization. Kenar et al.53 produced a
xeno-free, collagen/hyaluronic acid-based poly(L-lactide-co-ε-
caprolactone) (PLC/COL/HA) microfibrous scaffold by
electrospinning and, in coculture with human umbilical vein
endothelial cells, it promoted vessel formation.
2.1.2. Growth Factors/RNAs Delivery Systems. The
delivery of growth factors and RNAs has also been used to
promote the angiogenic process. Song et al.54 used a
heparinized decellularized adipose tissue (Hep-DAT) as a
delivery system of vascular endothelial growth factor (VEGF)
to study its vascularization potential. Human bone marrow
stromal cells (hBMSCs), seeded on this system, differentiated
into endothelial cells and promoted the formation of a vascular
network. Murali et al.55 developed a collagen-poly(dialdehyde)
guar gum-based hybrid porous scaffolds loaded with platelet
derived growth factor, which led to a higher cellular and
vascular response once implanted. Gümüsḑerelioğlu et al.56
immobilized it onto poly(2-hydroxyethyl methacrylate)-based
bone scaffolds. Angiopoietin-4 improved sprout formation,
which, together with VEGF (added to the scaffolds), promoted
vascularization. Zhang et al.57 developed angiogenic micro-
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carriers composed of sphingosine-1-phosphate (S1P) loaded
into mesoporous silica nanoparticles (MSNs), subsequently
embedded into porous nanofibrous poly-L-lactide (PLLA)
scaffold, which increased blood vessel formation. Li et al.58
enhanced miR-26a by developing a miRNA enhancer delivery
system, which led to increased vascularization and complete
repair of the critical-size calvarial bone defect in mice. Nelson
et al.59 developed a scaffold loaded with nanoparticles
containing siRNA. They show that this platform is highly
versatile for siRNA delivery in vitro or in vivo and leads to
increased vasculature in the scaffold. Nakasa et al.60 studied the
potential of local injection of double-stranded miR-1, miR-133,
and miR-206 to regenerate rat skeletal muscle injury and
observed an increase in neovascularization after injection.
Devalliere et al.61 developed an approach to make endothelial
cells more sensitive to the endogenous growth factors upon
implantation. Biodegradable PLGA polymer nanoparticles
were synthesized, loaded with miR-132, and coated with cyclic
RGD (cRGD) peptides that target an integrin produced by the
cultured human umbilical vein endothelial cells (HUVECs).
The nanoparticles slowly released RNA for several weeks,
leading to a 2-fold increase in the microvessel network and a
higher number of mural cell-invested vessels.
These angiogenic approaches present some disadvantages,
particularly for vascularization of bigger constructs. This is due
to the fact that on average, the growth rate of a microvessel is
approximately 5 μm/h, which implies that the cells within the
core of the implant will be hypoxic for a long period of time,
eventually leading to tissue loss.16
2.2. Prevascularization. A new approach called prevascu-
larization has been developed to overcome this issue. This
concept focuses on supplying the tissue constructs with a
preformed vascular network before their implantation in vivo so
that, once implanted, the network can be rapidly perfused with
blood by either fusing it with the surrounding host blood
vessels, inosculation, or by surgical anastomosis.16 There are in
vitro and in vivo approaches to prevascularization.
2.2.1. In Vitro Approaches. Cell seeding is an in vitro
approach that involves the seeding of vessel-forming cells on
the scaffolds before implantation. These scaffolds can be
synthetic or based on natural decellularized matrix, which
present the advantage of providing the ideal 3D template for
the cells. Endothelial cells have been the main source of cells
for this approach because they rapidly assemble into immature
vessels once exposed to different biomaterials, and, after
implantation, blood starts flowing within the first 10 days.16
Some disadvantages of the cell-seeding approach not only
include difficult and time-consuming harvesting and cultivation
processes but also the fact that the quality and number of the
cells isolated, and seeding strategy influences its safety and
success. Additionally, there needs to be a balance regarding the
amount of cells that are seeded into the scaffolds, as too many
significantly decrease vascularization even causing them to
regress. Another in vitro approach involves the development of
spheroids. These are clusters of cells, frequently used in
oncology, drug discovery, and toxicity as it is beneficial from a
biomimicry standpoint to utilize a 3D arrangement of cells.
Within the spheroid, cells have a higher cell-to-cell and cell−
matrix interaction similar to in vivo conditions of a
physiological tissue.62 There are several approaches to generate
these spheroids and there also different types of cells that can
be used. Spheroids can be implanted once prevascularized with
studies showing that connections between the host blood
vessels and the vessels within the spheroid can be established.
This allows the rapid initiation of blood perfusion.63,64 Lastly,
cell sheet technology is based on the lack of a scaffold to
culture cells. That technique has been used to promote the
survival of skin flaps, showing a higher blood perfusion once
implanted in vivo65 and for cardiac remodeling, with
stimulation of neovascularization and cardiomyocyte prolifer-
ation,66 and will be further discussed in section 4.
2.2.2. In Vivo Approaches. In in situ approaches, the body is
used as a bioreactor to promote the formation of new
functional microvessels within the scaffolds. This approach
involves the introduction of a scaffold into an easily accessible
and well-vascularized tissue of the body. Over time, an
angiogenic response is induced leading to a random growth of
new vessels from the host vasculature. Then the scaffold is
removed and transferred to the target site and the blood starts
flowing into the newly formed vessels of the scaffold via
inosculation. A disadvantage of this process is the need of at
least three surgical interventions (the first introduction of the
scaffold for prevascularization, the surgical removal of the
prevascularized scaffold and finally the implantation into the
target site). Additionally, it is a time-consuming process, and
the success of connecting the preformed vessels of the scaffold
and the host vessels upon implantation into the target site is
dependent on their growth after final implantation. Thus, an
immediate blood perfusion is difficult to achieve. To overcome
this issue, methods have been developed to surgically unite the
vessels from the scaffold and the host.16 The flap technique is
focused on the implantation of a scaffold into a muscle flap to
promote its neovascularization from the surrounding tissue.
Then the prevascularized scaffold is transferred to the target
site, and the newly formed vessels and the host vessels are
surgically anastomosed. A major advantage of this technique is
the immediate perfusion of the scaffold after final implantation.
However, tissue loss can occur, and optimization of the
materials and growth factor doses used for the prevasculariza-
tion step is needed.16 The arteriovenous (AV)-loop technique
takes advantage of the spontaneous sprouting of vessels
generated by an arteriovenous fistula shaped as a loop. A
polycarbonate growth chamber is used to place the loop, along
with a suitable ECM, allowing prevascularization. The
construct is then implanted into the target site and surgically
anastomosed to the host vasculature. The lack of major tissue
loss and deformation is an advantage of this technique
compared to the flap technique.16
2.2.3. Other Approaches. Microfabrication technologies
and microfluidic systems have also been developed for
vascularization. Creating hollow microchannels in the tissue
constructs can be achieved through microfabrication. This can
be produced using sacrificial materials that provide shape to
the vessels. This prefabrication of vessels into the scaffolds can
improve the cell viability upon perfusion.67,68 For example, a
glucose-sensitive hydrogel that can be removed by addition of
cell culture medium was used as a sacrificial material to
introduce vascularity in constructs.69 Another way to achieve
hollow microchannels is by decellularization of organs and
tissues.70,71 Microfluidic systems are focused on the controlled
formation of branches within hydrogels, which can later be
seeded with ECs through perfusion. A major advantage of this
method is improved cell viability due to continuous flow of
oxygen and nutrients and removal of waste products. A
drawback of these systems is the lack of similarity to the
physiological environment.16
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Microcontact imprinting is a 2D patterning technique that
can introduce patterns of adhesive proteins on noncell-
adhesive substrates, which will then allow the migration and
sprouting of these capillary-patterned cells into the hydro-
gels.67 Wong et al.71 have shown that a vascular-branching
pattern can be transferred using this technique. Photo-
lithography is based on the generation of specific patterns
onto a photomask, which is positioned on top of photo-cross-
linkable biomaterials. Only the areas exposed to light will be
cross-linked; therefore, remaining material can be washed
away, thus creating organized microchannels.67 3D bioprinting
is another option to create a vascular network. It involves the
fabrication of scaffolds and the precise placement cells into a
predetermined position.16 Contractible endothelialized my-
ocardium can be generated by seeding cardiomyocytes into 3D
bioprinted microfibers and ECs.72 Some of these techniques
for vascularization in TE will be further explored throughout
this review.
3. ASSESSING THE ANGIOGENIC RESPONSE
The more frequently used angiogenic assays can be divided
into three major groups: in vitro, ex vivo, and in vivo, and these
are summarized in Table 1.
3.1. In Vitro Assays. These assays are used to study the
mechanistic of angiogenesis. The majority of these assays are
performed using ECs such as bovine aortic endothelial cells
(BAECs), human umbilical vein endothelial cells (HUVECs),
or human dermal microvascular endothelial cells (HDMECs).
These cells are heterogeneous, which in turn can lead to
different angiogenic responses. Together with the lack of
proximity to the physiological environment, the results
obtained by using these assays can sometimes be inconclusive.
Thus, these assays are usually used to obtain some preliminary
results regarding the potential of pro- or antiangiogenic
agents.73
3.1.1. Proliferation Assays. Assessing cell proliferation in
angiogenesis can lead to two results: that is, a pro-angiogenic
environment will lead to a low basal rate of vessel formation;
an antiangiogenic environment will lead to a high basal rate of
vessel formation. Some of the techniques used for this assay are
cell counting of ECs. Cells are labeled and subjected to a
angiogenic agent. Counting is usually performed using a
hemocytometer and a light microscope, making it a cheaper
and easily reproducible assay. However, the state of ECs cells
in vitro differs from their state in vivo. In physiological
conditions, ECs are predominantly in a quiescent state,
whereas in vitro, these cells tend to be in a proliferative state.
The use of a hemocytometer is prone to sampling error and
can only be used with a high density of cells. Not to mention
that it is time-consuming.73 Colorimetric assays can also be
used. Here, a biomolecule will be broken down by the ECs,
and the byproduct produced will be collected and directly
correlated with the EC population over time. A biomolecule
frequently used is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), which is processed by the
mitochondria in living cells and can be quantified using a
spectrophotometer. Thus, a faster MTT reduction over time
can be correlated to a growing cell population. Although this is
an easy assay to be performed, it presents some disadvantages
such as the fact that the cell metabolism can be altered by the
angiogenic agents in question and that a possible apoptotic
process can occur due to that metabolic alteration or due to a
possible cytotoxicity of the agent in question.73,74 DNA
synthesis assays are also an option to evaluate cell proliferation.
Tritiated thymidine (3H) or bromodeoxyuridine (BrdU) will
be introduced into the environment and during rapid mitosis
and consequent synthesis of new DNA in proliferative cells.
Either by evaluating the level of radioactivity brought by the
tritiated thymidine or by immunohistochemical detection of
BrdU, cell proliferation can be inferred. The use of tritiated
thymidine presents an obvious disadvantage due to its
Table 1. continued
aRepresentation of the techniques identified by ∗ were created using images from Smart Servier (https://smart.servier.com/), licensed under CC
BY 3.0 (http://creativecommons.org/licenses/by/3.0/).
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radioactivity, whereas the use of BrdU can be expensive while
providing results that can be difficult to interpret.73,75
Therefore, these assays should be complemented with other
assays to obtain more valuable information.
3.1.2. Migration Assays. Migration assays tend to focus on
understanding the movement of ECs when exposed to certain
biomolecules. This can be achieved by evaluating wound
healing potential. ECs are cultured to form a confluent
monolayer, which is then “wounded”. The damage will be
repaired by the proliferation and migration of the surrounding
cells. Usually, the proliferative process is eliminated by the
addition of a specific biomolecule to focus the study on the
migration potential. A disadvantage of this assay is the lack of
reproducibility regarding the initial confluency of cells and the
inherent difficulty in measuring movement, speed, and area
traveled by the cells.73 Another way to study migration is by
looking at the sprouting potential. HDMECs suspended in
fibrin cells are subjected to angiogenic growth factors and the
number of new sprouts and their respective length are
evaluated microscopically. In this assay, a major disadvantage
is the lack of similarity to the ECM and the basement
membrane of the materials used.73,76 Matrix degradation can
also be analyzed, as the basement membrane is disrupted
during the formation of new blood vessels. Degradation of
laminin-rich basement membrane and proteolysis of the
collagen-rich ECM occurs, thus leading to the release of
proteases such as matrix metalloproteinases (MMPs) and
aminopeptides. The zymogen assay, for example, is composed
of an artificial matrix, which will suffer the effect of proteases
harvested from the ECs. This is a relatively inexpensive
method that offers basic understanding regarding the activity
of MMPs. However, it is time-consuming, and its preparation
for multiple tests is difficult.73 The directionality of the cell
migration can also be assessed using a modified Boyden
chamber assay. The chamber is divided in two with a filter in
the center that allows migration; ECs are on one-half of the
chamber and the biomolecule under study is placed on the
other half. The ECs will migrate in response to the chemical
signal, the membrane will be dyed, and the number of cells that
went through it can be counted. This is also a quick method to
perform, and its sensitivity to alterations in chemical
concentrations is also an advantage. On the other hand, the
filters used can be expensive due to their coating with matrix
proteins.73,77 Phagokinetic track assays are also used to
quantify ECs migration. A substrate covered with gold
nanoparticles is used to place the ECs and a chemical stimulus
is added. The movement of the cells will be engraved in the
colloidal gold, which can be used to study their direction and
total movement. A major disadvantage of this method is its
lack of similarity to physiological conditions.73,77
3.1.3. Tube Formation Assays. These assays focus on the
step of tubulogenesis, which allows the connection between
new and existing vessels. Matrigel assays are a way to evaluate
this process. ECs are placed on Matrigel, which tends to mimic
the ECM, and the tube formation can be analyzed with
imaging techniques. Data can only be collected in cases where
ECs are plated entirely without the presence of fibroblasts or
cancerous cells, and the existence of lumens within the
capillary-like structures should also be verified.73 Although this
is typically a two-dimensional method, it can also be performed
to assess angiogenesis in three-dimensions. ECs are grown and
plated between layers of Matrigel, and generally, tubes are
formed horizontally between layers. This presents a more
accurate representation of the physiological environment but it
also makes it more difficult and time-consuming to analyze
tube formation.73,78 Coculture assays can also be used to assess
tubulogenesis. A coculture model is composed by a two-
chamber well, separated by a porous polycarbonate membrane.
What is cultured in each chamber can be manipulated and,
depending on the presence of a stimulant or an inhibitor, ECs
will sprout and form capillaries or reduce their activity,
respectively. ECs are then stained with a specific antibody,
CD31/PECAM, and imaged microscopically.73,77
3.2. Ex Vivo Assays. 3.2.1. Thoracic Aorta Ring (TAR).
This is one of the most used methods to study the angiogenic
process. The aorta is dissected, placed in either collagen or
fibrin gels, and cultured in serum-free media, allowing vessel
sprouting. The sprouts can be measured by staining and
microscopic observation. The TAR method has several
advantages such as being physiologically relevant with new
vessel formation with the support of the surrounding cells. It is
a relatively fast and inexpensive assay, scalable, with minimum
inflammatory response. Clear and visible tubes are formed and
developed in a time scale similar to that in vivo. It is not time-
consuming and allows the assembly of different types of data.
However, it requires fresh tissue, it does not completely mimic
the physiological conditions because other tissues are not
involved, and there is no blood flow. Additionally, vessel
regression occurs, limiting the analysis over time.73,79
3.2.2. Ex Vivo Retina Angiogenesis. In this method, new
vessels form from mature and quiescent pre-existing retinal
vessels. A three-dimensional fibrin gel is used to culture
fragments of retina obtained from adult mice. In the presence
of human recombinant VEGF, endothelial cells start sprouting
into the fibrin gel and can be observed over time using an
inverted microscope. The ability to evaluate potential pro-
angiogenic factors and the precise analysis of new sprouts from
pre-existing adult retina vessels are some of the advantages of
this method. On the other hand, there are no circulating
endothelial progenitors, hormonal factors, and blood flow,
which all have a great influence on the angiogenic process.73,80
3.3. In Vivo Assays. In vivo assays generally obtain more
reliable information on the influence of the biomolecule or
material in question, within an organism. A final confirmation
of results using these assays should always be complemented
with information obtained from in vitro studies.
3.3.1. Chick Chorioallantoic Membrane (CAM). This is an
old and frequently used assay that is based on the existence of
the chorioallantoic membrane in fertilized eggs, which hosts a
considerable vessel network. After a few days of incubation, a
small piece of shell is cut off to access the CAM. The “window”
is closed to protect the membrane and the eggs are incubated
for a few more days. The “window” is opened, the agent is
placed on top of the CAM, the “window” is closed, and the
eggs are incubated once more. After this final incubation step,
the region of the membrane that hosts the agent is removed
from the egg and imaged. An alternative CAM method can also
be performed, where the embryo is removed from the shell and
cultured in a Petri dish before the agent is introduced. The
CAM assay is frequently used due to its easy technical
reproducibility, ability to do large-scale screening, inexpensive-
ness, and ease of observation of new vascularization.
Additionally, ethically speaking, this method is the most
acceptable to study angiogenesis in vivo. However, it is not the
easiest method to use for weak pro-angiogenic agents due to
the numerous blood vessels present in the CAM.73,81
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3.3.2. Zebrafish Assay. The zebrafish assay is, in many ways,
a very advantageous method to use. It involves the injection of
a test agent into the yolk sac. In case of lipophilic agents, these
can freely enter the embryos by diffusion. The effects on
vascularization can be observed due to the transparency of the
zebrafish embryos that develop outside the mother. Addition-
ally, the vasculature can be highlighted via fluorescent dyes,
quantum dots, or microspheres and analyzed by confocal
microscopy and image reconstruction. Thus, the rapid
development, transparency, and easy genetic manipulation of
the zebrafish embryos, together with the numerous offspring
per birth, makes this assay very appealing. Moreover, the
cardiovascular system appears very early in the zebrafish
development, facilitating the observation of the angiogenic
process, and studies have shown that the molecular pathways
between fish and mammals are conserved, which allows direct
translation of the findings in this zebrafish model into potential
information for human health. However, the type of
vascularization that occurs must be distinguished between
angiogenesis and vasculogenesis.5,73,82
3.3.3. Corneal Angiogenesis Assay. The corneal angio-
genesis assay takes advantage of the natural lack of blood
vessels in the cornea to visualize and assess new vascular
formation. This method is performed by creating a stromal
“pocket” immediately behind the cornea, where the angiogenic
agent will be placed. Usually, the delivery of these agents is
done progressively, with the help of slow-release pellets or
sponges. These new vessels can then be stained and the images
can be analyzed. This method is quantitative, easy to reproduce
and to visualize, and does not need a background measurement
due to the lack of vessels in the tissue. Thus, vessels observed
in the cornea only result form the angiogenic process.
However, it comes with associated ethical issues since it
manipulates an important organ of a living animal. It is a costly
process, and the methods used to form stromal pockets need to
be improved.73,83
3.3.4. Matrigel Plug Assay. The Matrigel plug is another
common assay to study angiogenesis. Matrigel is used not only
due to its similarity to the ECM but also because it exists as a
liquid state at cold temperatures (4 °C) and gelfies when
subjected to warmer temperatures (37 °C). Thus, in this
method, subcutaneous injection of Matrigel or implantation of
a polymer scaffold is performed, usually in rat or mouse, and
once solidified, angiogenic agents are inserted via slow-release
pellets or sponges. Following an incubation step, the Matrigel
plug is removed, stained, and imaged. The vessels present in
the plug can be measured using endothelial markers or by
analyzing the hemoglobin content. Some disadvantages of this
method are the fact that Matrigel is expensive and the
possibility of systemic error in the data due to the use of
different sponges containing slow-release pellets5,73
3.3.5. Chamber Assays. The creation of a transparent
chamber has also been used to assess angiogenesis. In the
rabbit ear chamber assay, a piece of skin is removed and the
Figure 4. Stimulation/control of angiogenesis in TE constructs. (a) Evaluation of volumetric skeletal muscle tissue reconstruction after creation of
Tibialis anterior (TA) muscle injury and multiple cell injections in a progressive manner. Quantitative analysis of TA muscle thickness, mass, and
function (N kg−1) after both C2C12 and hMPC injection. (b) HE and immunofluorescence staining of capillaries onto PCL scaffolds, scale bar =
100 μm, using different concentrations of VEG-Fc. Quantity of capillaries in each scaffold was quantified. The data indicate means ± SD of n = 3
experiments. ∗∗∗P < 0.001; ∗∗P < 0.01; ∗P < 0.05. (a) Reproduced from ref 94. Copyright 2016, The Authors. (b) Reproduced from ref 86 with
permission from The Royal Society of Chemistry, 2018.
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angiogenic agent is introduced on the exposed area, which is
then covered by glass. After the animal recovery, gene
expression, angiogenesis, pH and blood flow can be measured
in a living organism. This model has been used to study
structural and functional changes in the formation of new
vessels in tumors.84 In the dorsal skinfold chamber, the
protocol is similar but it has been used to introduce xenografts
in immunodeficient rodents and to understand the role of the
angiogenic process in tumor growth and wound healing. For
the cranial window chamber, a part of the skull is removed to
create the transparent chamber. This method has been used to
understand pial microcirculation. The results obtained using
these assays can be quantified using microscopy. 3D vessel
growth throughout 1−3 weeks using only one animal is a
major advantage of these assays since it allows reducing the
number of animals used. However, these are invasive,
technically demanding, and time-consuming assays. Addition-
ally, due to the thickness of the skin, it is difficult to observe
the vessels in the skinfold chamber and, in the cranial window
assay, the use of fluorescent markers is needed for imaging of
new vessels.77,85
3.3.6. Dorsal Air Sac Assay. The dorsal skin air sac model
has been used to understand angiogenesis triggered by tumors.
For this technique, a chamber is created with Millipore rings
and filters, and then a tumor cell suspension is injected into
this chamber. An air pocket is created on the dorsum of a rat,
which forms a temporarily isolated vascularized membrane,
and the chamber is placed inside. The chamber is then
removed and newly formed vessels can be counted using a
dissecting microscope. This method is relatively easy to use but
attention is required for the creation of the chamber, avoiding
irritation of the surface since this itself can lead to
neovascularization and mask the vascularization initiated by
the presence of the tumor.77
4. STIMULATING/CONTROLLING ANGIOGENESIS IN
TE CONSTRUCTS
4.1. Angiogenic Growth Factor (AGF) Delivery. With
respect to physiological considerations, there is a set of factors
that play a crucial role during the formation of new vessels.
Vascular endothelial growth factor (VEGF) is responsible for
the differentiation of angioblasts with new sprouts induced by
angiopoietins. The stabilization of these new vessels is
regulated by platelet-derived growth factor (PDGF) and
transforming growth factor- β1 (TGF-β1). It involves
recruiting vascular smooth muscle cells (SMCs) and pericytes,
as well as ECM formation. At this step of neovascularization,
other factors such as blood flow, shear stress, and presence of
oxygen are of utmost importance, ultimately releasing VEGF
from its role and assuring the independence of the endothelial
cells. Finally, matrix metalloproteinases release pro-angiogenic
factors present in the matrix, regulate further branching, and
remodel new vessels.86 Thus, the incorporation of these pro-
angiogenic factors into the constructs have also been explored
as a way to stimulate and control angiogenesis in constructs
(Figure 4). Xu et al.86 developed a polycarprolactone (PCL)
porous scaffold with a bioactive interface composed of human
VEGF fused with an immunoglobulin G Fc region (VEGF-Fc).
This formulation not only improved adhesion and proliferation
of human vascular endothelial cells (HUVECs), but it also
promoted the migration of these cells into the scaffolds,
leading to neovascularization in vivo. Correa do Amaral et al.87
added PDGF-BB to a collagen-glycosaminoglycan (CG)
scaffold to avoid regression of the newly formed vessels.
After 10 days of culture, the added growth factor stabilized the
new vasculature, which was further confirmed by analysis of
the expression of certain angiogenic genes. To better mimic the
spatiotemporal delivery of growth factors, the use of several
growth factors with controlled release has been studied. Awada
et al.88 embedded VEGF in fibrin gel with a distribution of
PDGF in a heparin-based coacervate. In a rat model, the
sequential delivery of these growth factors promoted the
formation and stabilization of newly formed vessels, thus
promoting cardiomyocyte survival. Chiu and Radisic89
developed 3D-porous collagen scaffolds with VEGF and
Angiopoietin-1 (Ang1). Culturing over a few days led to
increased proliferation of endothelial cells into the scaffolds.
4.2. Cell-Based Strategies. Another approach to control/
stimulate vascularization is based on the use of cells (Figure 4).
The coculture of cells promotes the development of a vascular
network. Coculture with fibroblasts, keratinocytes, pericytes
and vascular smooth muscle cells, which are responsible for
providing structure to vascular walls in vivo, can enhance
differentiation of cultured endothelial cells, promoting vessel
formation.2 Kim et al.90 developed a triculture system
composed of human pericytes, fibroblasts, and endothelial
cells, to promote vascularization of a nanografted substrate
composed of polydimethylsiloxane in vitro. Capillary-like
tubular structures formed with subsequent ECM formation,
displaying that the triculture system promotes angiogenesis.
Mesenchymal stem cells (MSCs) have also been used in
coculture with endothelial cells. Freiman et al.94 cocultured
adipose-derived MSCs with human adipose-derived micro-
vascular endothelial cells (HAMECs) to promote vasculariza-
tion in a three-dimensional scaffold, in vitro. A well organized
and complex vasculature was formed in a short period of time.
Another approach of cell-based strategies for vascularization is
cell sheet technology. It uses a temperature responsive surface
that allows the harvesting of an intact cell sheet. This is
achieved by treating them with poly(N-isopropylacrylamide)
(PIPAAm), which oscillates between hydrophilic and hydro-
phobic states according to the temperature. Temperatures
higher than 32 °C lead to a hydrophilic state, which means that
at a regular culture temperature (37 °C), PIPAAm offers a
normal cell culture environment. However, at temperatures
lower than 32 °C, the surface state is changed to hydrophobic
and the rapid hydration and swelling of PIPAAm leads to a
spontaneous detachment of the cell sheet.91 Some clear
advantages of this technology are the easy manipulation of the
cells and the maintenance of cell-to-cell interactions and ECM
development, which is usually damaged by treatment with
trypsin. Alternatively, to the thermoresponsive approach, there
are also electro-, photo-, pH-, and magnetic-responsive
systems. The cell sheet, when formed by fusion with a
rolled-up edge, can also be harvested by the mechanical peeling
method. The thermoresponsive approach is sensitive to the
thickness and density of the grafted polymer chains. Both
electro- and magnetic-responsive approaches may add residual
materials to the cell sheets. In the mechanical peeling method,
the manipulation of the cells91 can be challenging.92 Ren et
al.15 developed a synthetic biomimetic induced membrane
(BIM) with an inner highly prevascularized cell sheet and an
outer osteogenic layer for the treatment of bone defects.
Results showed a significant development of vascular-like
networks and, after implantation of the construct, rapid
vascularization and anastomosis to the host vessels occurred.
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Sakaguchi et al.92 constructed 3D tissues by layering cell
sheets. For that, there is a need of medium and blood perfusion
within the different cells’ sheets, thus two types of vascular
beds were developed. Functional vascularized 3D tissues were
developed. Additionally, the progressive layering technique can
also be used, which takes advantage of the natural host
regeneration process for vascularization.2 Kim et al.93
performed multiple injections of cells, in a progressive manner,
in a rodent volumetric muscle loss (VML) model. The muscle
tissue was successfully reconstructed, including integration of
host vasculature and neurons, with function recovered.
4.3. Intelligent Scaffold Design. Intelligent scaffolds
arouse from the realization that the ECM not only provides
support for the cells but also regulates functions such as
proliferation, migration, differentiation, among others.95 Thus,
these “smart” scaffolds tend to mimic this dynamic nature of
the ECM by being biodegradable, enabling their reabsorption
without secondary effects, and bioactive, eliciting a specific cell
response.96 Aguirre et al.96 developed a smart polylactic acid
(PLA)/calcium phosphate glass composite biomaterial to
mimic the high extracellular calcium concentration present in
bone healing microenvironment as well as the matrix stiffness
provided by the osteoid. Angiogenesis was improved due to
the activation of angiogenic pathways by the scaffold. Cui et
al.97 integrated a biomimetic 3D bioprinted fluid perfused
microstructure with a smart release nanocoating. There was a
successive induction of angiogenesis and osteogenesis via a
spatiotemporally coordinated delivery of dual growth factors.
Hokugo et al.98 focused on chemotaxis. They developed an
apatite-coated polylactic-co-glycolic acid scaffold where en-
gineered human mesenchymal stem cells overexpressing VEGF
were seeded. The continuous release of VEGF attracts
mesenchymal stem cells to the site of injury, inducing
angiogenesis and subsequently promoting tissue regeneration.
4.4. Immobilization of Molecules. There are several
ways to immobilize molecules either on the surface or inside
constructs. Surface immobilization of biomolecules can be
achieved by chemical incorporation, which can be via
noncovalent or covalent methods. Noncovalent incorporation
(physical adsorption) takes advantage of surface interactions
such as van der Waal forces, electrostatic forces, hydrophobic
interactions and hydrogen bonds. Noncovalent incorporation
presents advantages like simplicity and, in the case of fragile
structures or biomolecules, it is quite benign.99 For example,
Park et al.100 loaded gelatin microparticles (MPs) with
transforming growth factor-β1 (TGF-β1) via noncovalent
incorporation. The MPs were immersed in an aqueous TGF-
β1 solution at pH 7.4 for 15 h. While covalent incorporation is
based on chemically bonding biomolecules to a relevant
functional group in the scaffold. This is a more efficient bond
as the biomolecules are retained for a longer period of time.
Chiu and Radisic,89 developed 3D porous collagen scaffold and
covalently immobilized VEGF and Ang1 onto it. Increased
proliferation of endothelial cells and infiltration in the CAM
assay was observed. Miyagi et al.101 developed an ultrafoam
collagen sponge scaffold with VEGF covalently immobilized
onto it, with the aim to replace a full right ventricular free wall
defect in rat hearts. In vivo, neovascularization was observed
with improved cell survival and tissue formation. Another
surface immobilization technique takes advantage of linker
molecules, and it is usually used when the biomolecules cannot
be directly grafted onto the polymer surface. These linker
molecules will bind to the biomolecule and then to the
biomaterial surface.99 Guo et al.102 used a glycosaminoglycan
as a linker molecule. The authors developed a self-assembling
peptide, heparin-binding domain sequence attached to a self-
assembling peptide, which in turn attaches to the nanofiber
scaffold under physiological conditions. This allowed a
sustained release of VEGF, improving cardiac function and
microvessel density. Layman et al.103 opted to use components
from the ECM as a linker molecule. The authors
coimmobilized FGF-2 and human recombinant granulocyte
colony-stimulating factor (G-CSF) into gelatin-based hydrogel
scaffolds, promoting mature vessel formation in a murine
hindlimb ischemic model. Davis et al.104 explored the avidin−
biotin binding system. The aim was to design a self-assembling
peptide nanofiber for sustained delivery of insulin-like growth
factor 1 (IGF-1) into the myocardium. IGF-1 was biotinylated,
complexed with tetravalent streptavidin and bound again to a
biotinylated self-assembling peptides, which was in turn
attached to the nanofibers.
Regarding incorporation of biomolecules into the core of
constructs, techniques such as direct mixing, coaxial incorpo-
ration (electrospinning), and self-assembling (amphiphile)
peptide nanofibers can be used. In this case, it can be a
continuous release of biomolecules by diffusion or degradation
of the polymer.99 In the direct mixing technique, the
biomolecules and the polymer solution can be directly mixed
as the name suggests. For example, Ruvinov et al.105
incorporated a biconjugate composed of hepatocyte growth
factor (HGF) with alginate-sulfate into an alginate hydrogel.
This injectable biomaterial enabled sustained release of HGF
in a severe murine hindlimb ischemia model, promoting
neovascularization as well as blood perfusion. Kraehenbuehl et
al.106 developed a synthetic, injectable matrix metalloprotei-
nase (MMP)-responsive, bioactive hydrogel for thymosin β4
(Tβ4) and vascular cells derived from human embryonic stem
cells (hESC). In an ischemic injury in a rat model, the scaffold
promoted the formation of new blood vessels. Another bulk
incorporation technique involves the self-assembling peptide
nanofibers where biofunctional peptide sequences are incorpo-
rated into amphiphile peptides, which in turn self-assemble
into nanofibers.99 Lin et al.107 developed RAD16-II peptide
nanofibers for intramyocardial injection to promote cardiac
remodeling in a pig model. The injection of the peptide
nanofibers along with bone marrow cells (MNCs) increased
angiogenesis after infarction. Kim et al.108 used the self-
assembling peptides for dual delivery of growth factors PDGF-
BB and FGF-2. The formation of new vessels was observed
leading to improved cardiac function.
5. CONCLUSION
Looking to the future, a highly organized vascular network that
is able to supply all cells with sufficient nutrients needs to be
achieved in an optimal tissue engineered structure, comprising
venules, capillaries, and arterioles. Introducing spatially
controlled micro patterns into the developed constructs,
using bioprinting techniques, for example, can promote the
direct perfusion of blood after implantation. However, some
authors argue that patterning vascular cells in engineered
tissues may not be sufficient to ensure a good vascular
organization in the long term as the vasculature is likely to
revert to a disorganized state upon implantation without
additional cues. However, the authors do agree that patterning
of endothelial cells will provide a valid starting point. Because
of the myriad of varying tissue types, it is unlikely that one
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single optimal method to add a vascular network to engineered
tissues will be realized rather a mix of various cell types form
differing sources will be utilized. Therefore, it is of critical
importance that in vitro and in vivo methods utilized to assess
vascularization degree and structure continue to be developed.
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